S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:CYAD

Celyad Oncology News Headlines

$3.67
-0.12 (-3.17%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.55
$3.68
50-Day Range
$3.67
$5.00
52-Week Range
$3.55
$10.31
Volume
8,951 shs
Average Volume
33,290 shs
Market Capitalization
$59.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35

Media Mentions By Week



Celyad Oncology Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYAD
News Sentiment

0.50

0.26

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYAD Articles
This Week

2

0

CYAD Articles
Average Week

Get Celyad Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

Celyad Oncology (NASDAQ:CYAD) News Headlines Today

SourceHeadline
MarketBeat logoCelyad Oncology (NASDAQ:CYAD) Stock Passes Below Fifty Day Moving Average of $4.30
americanbankingnews.com - November 24 at 3:20 AM
MarketBeat logoFY2021 EPS Estimates for Celyad Oncology SA Lifted by William Blair (NASDAQ:CYAD)
americanbankingnews.com - November 15 at 2:16 AM
finance.yahoo.com logoCelyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
finance.yahoo.com - November 12 at 8:48 AM
finance.yahoo.com logoCelyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights
finance.yahoo.com - November 10 at 8:49 PM
finance.yahoo.com logoCelyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition
finance.yahoo.com - November 4 at 10:19 AM
finance.yahoo.com logoCelyad Oncology Announces November 2021 Conference Schedule
finance.yahoo.com - November 2 at 3:37 AM
finance.yahoo.com logoCelyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - October 1 at 8:39 AM
barrons.com logoCelyad Oncology S.A. ADR
barrons.com - August 21 at 6:42 PM
barrons.com logoCelyad Oncology S.A.
barrons.com - August 19 at 7:10 AM
finance.yahoo.com logoCelyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
finance.yahoo.com - August 4 at 7:36 PM
finance.yahoo.com logoCelyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
finance.yahoo.com - July 30 at 2:21 AM
finance.yahoo.com logoCelyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
finance.yahoo.com - July 20 at 6:38 PM
businesswire.com logoCelyad Oncology to Host Virtual Research & Development Webinar on July 20 th
businesswire.com - July 14 at 3:38 AM
finance.yahoo.com logoCelyad Oncology to Host Virtual Research & Development Webinar on July 20th
finance.yahoo.com - July 13 at 5:22 PM
finance.yahoo.com logoCelyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
finance.yahoo.com - July 7 at 8:37 PM
finance.yahoo.com logoTransparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)
finance.yahoo.com - May 19 at 1:40 AM
msn.com logoThe Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
msn.com - May 13 at 10:12 AM
finance.yahoo.com logoCelyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy
finance.yahoo.com - May 13 at 10:12 AM
finance.yahoo.com logoCelyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
finance.yahoo.com - May 12 at 6:54 PM
finance.yahoo.com logoCelyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights
finance.yahoo.com - May 6 at 6:30 PM
benzinga.com logoTransparency Notification Received from Tolefi SA...
benzinga.com - May 5 at 12:28 PM
businesswire.com logoCelyad: Transparency Notification Received From Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
businesswire.com - May 5 at 12:28 PM
finance.yahoo.com logoTransparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
finance.yahoo.com - May 5 at 12:28 PM
benzinga.com logoInformation on the Total Number of Voting Rights...
benzinga.com - April 30 at 9:01 AM
businesswire.com logoCelyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
businesswire.com - April 30 at 9:01 AM
finance.yahoo.com logoInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
finance.yahoo.com - March 31 at 10:34 AM
seekingalpha.com logoCelyad Oncology's (CYAD) CEO Filippo Petti on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 27 at 3:42 PM
benzinga.com logoCelyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights | Benzinga
benzinga.com - March 26 at 6:33 PM
finanznachrichten.de logoCelyad Oncology SA: Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
finanznachrichten.de - March 26 at 6:33 PM
finance.yahoo.com logoCelyad Oncology SA to Host Earnings Call
finance.yahoo.com - March 25 at 3:33 PM
finance.yahoo.com logoCelyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 24 at 7:46 PM
sg.finance.yahoo.com logoCelyad Oncology SA (CLYYF)
sg.finance.yahoo.com - March 19 at 10:11 AM
finance.yahoo.com logoCelyad Oncology Announces March 2021 Conference Schedule
finance.yahoo.com - March 1 at 7:04 PM
finance.yahoo.com logoCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
finance.yahoo.com - January 20 at 5:27 PM
finance.yahoo.com logoInformation on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
finance.yahoo.com - January 20 at 5:27 PM
finance.yahoo.com logoCelyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
finance.yahoo.com - January 19 at 5:35 PM
seekingalpha.com logoDosing underway in Celyad's early-stage colorectal cancer study with CAR T candidate
seekingalpha.com - December 17 at 4:03 AM
nasdaq.com logoCelyad Oncology Discontinues Autologous CAR T Candidate CYAD-01; CYCLE-1 CYAD-02 Trial Ongoing
nasdaq.com - December 7 at 4:07 AM
finance.yahoo.com logoCelyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
finance.yahoo.com - December 7 at 4:07 AM
finance.yahoo.com logoCelyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma
finance.yahoo.com - December 4 at 2:51 AM
finance.yahoo.com logoCelyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit
finance.yahoo.com - December 1 at 6:47 PM
nasdaq.com logoCelyad Oncology SA Rings the Nasdaq Stock Market Opening Bell
nasdaq.com - November 24 at 1:57 PM
finance.yahoo.com logoCelyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - November 10 at 8:43 PM
finance.yahoo.com logoCelyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
finance.yahoo.com - November 4 at 5:34 PM
finance.yahoo.com logoCelyad Oncology Announces November 2020 Investor Conference Schedule
finance.yahoo.com - November 2 at 5:35 PM
finance.yahoo.com logoThe Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut
finance.yahoo.com - October 19 at 6:53 PM
in.finance.yahoo.com logoCELYAD ONCOLOGY S.A. (1C0.MU)
in.finance.yahoo.com - October 14 at 10:46 PM
seekingalpha.com logoCelyad to evaluate CYAD-101/KEYTRUDA combo in colorectal cancer
seekingalpha.com - September 29 at 11:49 AM
seekingalpha.com logoCelyad to evaluate CYAD-101/KEYTRUDA combo in early stage colorectal cancer study
seekingalpha.com - September 29 at 11:49 AM
benzinga.com logoCelyad Oncology Announces Clinical Trial...
benzinga.com - September 29 at 6:48 AM
Get Celyad Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.